Skip to main navigation Skip to search Skip to main content

The protective PLCγ2-P522R variant mitigates Alzheimer’s disease-associated pathologies by enhancing beneficial microglial functions

  • Mari Takalo
  • , Heli Jeskanen
  • , Taisia Rolova
  • , Inka Kervinen
  • , Marianna Hellén
  • , Sami Heikkinen
  • , Hennariikka Koivisto
  • , Kimmo Jokivarsi
  • , Stephan A. Müller
  • , Esa Mikko Koivumäki
  • , Petra Mäkinen
  • , Sini Pauliina Juopperi
  • , Roosa Maria Willman
  • , Rosa Sinisalo
  • , Dorit Hoffmann
  • , Henna Jäntti
  • , Michael Peitz
  • , Klaus Fließbach
  • , Teemu Kuulasmaa
  • , Teemu Natunen
  • Susanna Kemppainen, Pekka Poutiainen, Ville Leinonen, Tarja Malm, Henna Martiskainen, Alfredo Ramirez, Annakaisa Haapasalo, Stefan F. Lichtenthaler, Heikki Tanila, Christian Haass, Juha Rinne, Jari Koistinaho, Mikko Hiltunen
  • University of Kuopio
  • University of Helsinki
  • German Center for Neurodegenerative Diseases (DZNE)
  • Technical University of Munich
  • University of Turku and Turku University Hospital
  • Turku University Hospital
  • University of Bonn
  • University of Bonn and University Hospital Bonn
  • Kuopion Yliopistollinen sairaala
  • University of Cologne
  • the University of Texas Health Science Center at San Antonio
  • University of Cologne
  • Munich Cluster for Systems Neurology (SyNergy)
  • University of Munich

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Background: Phospholipase C gamma 2, proline 522 to arginine (PLCγ2-P522R) is a protective variant that reduces the risk of Alzheimer’s disease (AD). Recently, it was shown to mitigate β-amyloid pathology in a 5XFAD mouse model of AD. Here, we investigated the protective functions of the PLCγ2-P522R variant in a less aggressive APP/PS1 mouse model of AD and assessed the underlying cellular mechanisms using mouse and human microglial models. Methods: The effects of the protective PLCγ2-P522R variant on microglial activation, AD-associated β-amyloid and neuronal pathologies, and behavioral changes were investigated in PLCγ2-P522R knock-in variant mice crossbred with APP/PS1 mice. Transcriptomic, proteomic, and functional studies were carried out using microglia isolated from mice carrying the PLCγ2-P522R variant. Finally, microglia-like cell models generated from human blood and skin biopsy samples of PLCγ2-P522R variant carriers were employed. Results: The PLCγ2-P522R variant decreased β-amyloid plaque count and coverage in female APP/PS1 mice. Moreover, the PLCγ2-P522R variant promoted anxiety in these mice. The area of the microglia around β-amyloid plaques was also increased in mice carrying the PLCγ2-P522R variant, while β-amyloid plaque-associated neuronal dystrophy and the levels of certain cytokines, including IL-6 and IL-1β, were reduced. These alterations were revealed through [18F]FEPPA PET imaging and behavioral studies, as well as various cytokine immunoassays, transcriptomic and proteomic analyses, and immunohistochemical analyses using mouse brain tissues. In cultured mouse primary microglia, the PLCγ2-P522R variant reduced the size of lipid droplets. Furthermore, transcriptomic and proteomic analyses revealed that the PLCγ2-P522R variant regulated key targets and pathways involved in lipid metabolism, mitochondrial fatty acid oxidation, and inflammatory/interferon signaling in acutely isolated adult mouse microglia and human monocyte-derived microglia-like cells. Finally, the PLCγ2-P522R variant also increased mitochondrial respiration in human iPSC-derived microglia. Conclusions: These findings suggest that the PLCγ2-P522R variant exerts protective effects against β-amyloid and neuronal pathologies by increasing microglial responsiveness to β-amyloid plaques in APP/PS1 mice. The changes observed in lipid/fatty acid and mitochondrial metabolism revealed by the omics and metabolic assessments of mouse and human microglial models suggest that the protective effects of the PLCγ2-P522R variant are potentially associated with increased metabolic capacity of microglia.

Original languageEnglish
Article number64
JournalJournal of Neuroinflammation
Volume22
Issue number1
DOIs
StatePublished - Dec 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Alzheimer’s disease
  • Lipid droplets
  • Microglia
  • PLCγ2-P522R variant
  • Phospholipase C gamma 2
  • β-amyloid pathology

Fingerprint

Dive into the research topics of 'The protective PLCγ2-P522R variant mitigates Alzheimer’s disease-associated pathologies by enhancing beneficial microglial functions'. Together they form a unique fingerprint.

Cite this